Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BYON3521
- Development stage
- Phase 1
- Lead developer
- Byondis
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BYON3521 is a novel antibody-drug conjugate (ADC) developed for the treatment of cancers that overexpress the c-MET protein. It consists of a humanized IgG1 monoclonal antibody (SYD2884) targeting c-MET, linked via a cleavable valine-citrulline linker to a duocarmycin-based cytotoxic payload (seco-DUocarmycin-hydroxyBenzamide-Azaindole, also known as vc-seco-DUBA or SYD980). Upon binding to c-MET on cancer cells, BYON3521 is internalized and releases its cytotoxic agent inside the cell, leading to targeted cell death. Preclinical studies have shown potent activity in MET-amplified and high MET-expressing tumor models as well as bystander killing effects. The drug aims to provide effective therapy with potentially fewer side effects than conventional chemotherapy by selectively targeting tumor cells[1][3][4][5][6].
- Other names
- anti-c-Met antibody-drug conjugate BYON3521SYD2884-vc-seco-DUBASYD-2884-vc-seco-DUBASYD 2884-vc-seco-DUBA
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on BYON3521.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BYON3521.